Clinical experience with lamivudine

Seminars in Liver Disease

Volumn 22, Issue SUPPL. 1, 2002, Pages 15-21

  Leung, Nancy ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antiviral resistance; Chronic hepatitis B; Hepatitis; Lamivudine; Nucleoside analogues

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALAISE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; SORE THROAT; TREATMENT OUTCOME; VIRUS RESISTANCE; VOMITING;

EID: 0036433207     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-35696     Document Type: Review

References (27)

1. Complete Prescribing Information for Epivir-HBV (Lamivudine). Research Triangle Park, NC: GlaxoSmithKline; 2001
2. Doong SL, Tsai CH, Schinazi RF, et al. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991;88:8495-8499
3. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial therapy for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263
4. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339: 61-68
5. Schiff E, Karayalcin S, Grimm R, et al. A placebo-controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 1998;28(Suppl):388A (Abst)
6. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435
7. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-180
8. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527-1532
9. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30: 567-572
10. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2000;12(Suppl):67-71
11. Lau DTY, Khokhar F, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32: 828-834
12. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-896
13. Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis treated for 12 months with lamivudine. J Hepatol 2000;32:300-306
14. Rizzetto M, Santantonio T, Buti M, et al. Benefits of extended lamivudine treatment in patients with HBeAg-negative HBV DNA-positive (pre-core mutant) chronic hepatitis B (CHB). Hepatology 2000;32:459A (Abst)
15. Cho SW, Hahm K-B, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000;32:1163-1169
16. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-851
17. Tassopoulos NC, Anagnostopoulos GD. Long-term lamivudine treatment of patients with precore mutant profile [HBeAg(-)/antiHBe(+)] chronic hepatitis B. Antivir Ther 2000;5(Suppl):34 (Abst)
18. Esteban R, Goldin RD, Tassopoulos NC, et al. Clinical and histological outcome of extended lamivudine in patients with HBeAg-negative chronic hepatitis B. Hepatology 2001;34: 446A (Abst)
19. Lok AS, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000;32:1145-1153
20. Liu CJ, Chen PJ, Lai MY, et al. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 2001;34:583-589
21. Seehofer D, Rayes N, Steinmuller T, et al. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. Liver Transpl 2001;7:976-982
22. Schvoerer E, Kabissa I, Cotto E, et al. Lamivudine therapy of chronic hepatitis B in three groups of patients: Nontransplanted patients, liver recipients, and kidney recipients. Gastroenterol Clin Biol 2002;26:62-66
23. Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002;122:264-273
24. Dore GJ, Cooper DA, Barrett C, et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). J Infect Dis 1999;180:607-613
25. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302-1306
26. Liaw YF. Management of patients with chronic hepatitis B. J Gastroenterol Hepatol 2002;17:406-408
27. Leung N. Treatment of chronic hepatitis B: Case selection and duration of therapy. J Gastroenterol Hepatol 2002;17:409-414